Alnylam Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 89 to 92.
How To Use Stock Charts To Stay Profitable And Protected
This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
History reveals that the best stocks often have an 80 or higher RS Rating in the early stages of their moves.
Alnylam Pharmaceuticals is building a double bottom with a 300.90 buy point. See if the stock can break out in volume at least 40% above average.
The company reported 0% earnings growth in its most recent report, while sales growth came in at 20%.
The company earns the No. 22 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and Eton Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
